financetom
Business
financetom
/
Business
/
MDA Space Q2 Net Income Rises; Updates 2025 Financial Outlook
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
MDA Space Q2 Net Income Rises; Updates 2025 Financial Outlook
Aug 7, 2025 4:27 AM

07:05 AM EDT, 08/07/2025 (MT Newswires) -- MDA Space ( MDALF ) , a partner to the global space industry, on Thursday said its second-quarter net income more than doubled.

The company reported net income of $27.2 million for the three months-ended June 30, compared with $11.0 million, a year earlier. Quarterly adjusted earnings per diluted share was $0.38, compared with $0.19, a year-ago, which beat consensus estimate compiled by FactSet of $0.30 per share.

Revenue for the quarter increased to $373.3 million, compared with $242.0 million, a year earlier, driven by higher volumes of work, primarily in its Satellite Systems business. The results were in-line with consensus estimate compiled by FactSet of $370.9 million and the company's guidance of between $360 million and $380 million.

For fiscal 2025, the company now expects full year revenues to be between $1.57 billion and $1.63 billion compared with $1.50 billion and $1.65 billion previously and full year adjusted EBITDA range to be between $305 million and $320 million compared with $290 million and $320 million, previously. MDA Space ( MDALF ) reaffirmed its expectations on capital expenditures to be between $210 million and $240 million, and full year free cash flow to be neutral to positive in 2025.

The company forecasts Q3 2025 revenues to be between $385 million and $415 million.

Shares of the company closed up 3.7% to $46.18 on Wednesday on the Toronto Stock Exchange.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Benefit of Eisai and Biogen's Alzheimer's drug increases over time, studies suggest
Benefit of Eisai and Biogen's Alzheimer's drug increases over time, studies suggest
Jul 30, 2024
CHICAGO, July 30 (Reuters) - The benefit of Eisai ( ESALF ) and Biogen's Alzheimer's drug Leqembi in patients with early-stage Alzheimer's appears to increase with continued use with no new safety issues, according to three-year data presented at an Alzheimer's meeting on Tuesday. In the companies' pivotal clinical trial, Leqembi reduced cognitive decline by 27% after 18 months -...
US warns airlines to follow passenger refund obligations
US warns airlines to follow passenger refund obligations
Jul 30, 2024
WASHINGTON, July 30 (Reuters) - U.S. Transportation Secretary Pete Buttigieg on Tuesday warned the 10 largest U.S. airlines they must comply with new passenger refund obligations passed by Congress in May. Buttigieg said in letters to airline CEOs that they must follow the new refund provisions and rejected an industry request for additional time. ...
Global accounting body wants more rigour in showing climate impacts
Global accounting body wants more rigour in showing climate impacts
Jul 30, 2024
LONDON (Reuters) - A global accounting body on Wednesday proposed guidance on how companies can do more to show the impact of climate change on their financial performance, saying standalone disclosures do not give investors the clarity they need. Norms written by the International Accounting Standards Board (IASB) are applied by listed companies in more than 140 jurisdictions, including the...
Stryker beats Q2 profit estimates on robust demand for medical devices, implants
Stryker beats Q2 profit estimates on robust demand for medical devices, implants
Jul 30, 2024
July 30 (Reuters) - Stryker Corp ( SYK ) posted an upbeat second-quarter profit on Tuesday, as demand for its medical and surgical devices rose, driven by growth in non-urgent surgeries. On an adjusted basis, the company reported a profit of $2.81 per share for the quarter ended June 30, slightly above analysts' estimates of $2.79 per share. The joint-implant...
Copyright 2023-2026 - www.financetom.com All Rights Reserved